Article Data

  • Views 1111
  • Dowloads 200

Reviews

Open Access

Vaping and subsequent comorbidities potentially associated with increased mortality and more severe illness in COVID-19: a narrative review

  • Kyle Blalock1
  • Frank Breve1
  • Giustino Varrassi2
  • Peter Magnusson3
  • Joseph Pergolizzi4

1School of Pharmacy, Temple University, Philadelphia, PA 19140 USA

2Paolo Procacci Foundation, 00193 Roma, Italy

3Centre for Research and Development, Region Gävleborg/Uppsala University, 803 20 Gävle, Sweden

4Clinical Research, Department of Analgesic Development, NEMA Research Inc., Naples, FL 34102, USA

DOI: 10.22514/sv.2021.113 Vol.17,Issue 6,November 2021 pp.25-36

Submitted: 30 April 2021 Accepted: 27 May 2021

Published: 08 November 2021

*Corresponding Author(s): Kyle Blalock E-mail: kyle.blalock@temple.edu

Abstract

Introduction: COVID-19 (or COVID) is a highly virulent viral disease which more frequently presents severe infection in specific populations, such as the elderly, patients with hypertension, patients with respiratory disease, and patients who smoke. The effects vaping (i.e., an electronic cigarette or JUUL device) has on COVID progression remains unclear, because there is an information paucity correlating e-cigarette use and COVID. This review sought to identify links between vape use and COVID severity via literature review. Additionally, because there is more widespread information about cigarette smoking than about vaping, this review sought to illustrate commonalities between smoking and vaping. If smoking and vaping are deemed near-identical practices, then it is possible the effects of smoking on human health and on COVID disease could be comparable in vaping.

Methods: Several searches were performed on PubMed with MeSH headings and JSTOR between 17 December 2020 and 22 December 2020. Search results were excluded if they were not trials or controlled clinical trials, if the articles were not about COVID, if the articles were about smoking behaviors or habits, or if the articles were not related to vaping or smoking. Key findings were summarized and tabled based on relevance, substantiability, and applicability to COVID.

Results: Multiple sources viewed smoking and vaping as equal risk factors for COVID disease, whereas other sources viewed the two as unique risk factors. Because of this controversy, it is challenging to view the two practices as similar enough to pose equivalent risks for COVID. Both practices pose significant health risks to its users, but these health risks are unique to each practice.

Discussion: There are several limitations which exacerbate ambiguity—(1) it is unclear how harmful smoking is for COVID patients, because several publications found smoking may have protective effects; (2) few older patients vape, but yet most severe COVID cases occur in older populations; (3) older patients and impoverished patients show a statistically significant risk for severe COVID disease independent of other factors; (4) vaping is a relatively new practice, and there are few patients who self-report long-term e-cigarette use or long-term adverse effects as a result thereof.

Conclusion: Although vaping may present serious health risks, clinically, it is uncertain how significantly vaping affects COVID disease, especially when compared against cigarette smoking. More research is needed on both the effects of vaping on COVID and the likeness of vaping versus smoking.


Keywords

COVID; Vaping; Vaping and COVID; Vaping and smoking; COVID mortality; COVID hospitalizations; EVALI; Nicotine exposure; Angiotensin converting enzyme-2


Cite and Share

Kyle Blalock,Frank Breve,Giustino Varrassi,Peter Magnusson,Joseph Pergolizzi. Vaping and subsequent comorbidities potentially associated with increased mortality and more severe illness in COVID-19: a narrative review. Signa Vitae. 2021. 17(6);25-36.

References

[1] Johns Hopkins University. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). 2021. Available at: https://coronavirus.jhu.edu/map. html (Accessed: 13 May 2021).

[2] Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian Journal of Pediatrics. 2020; 87: 281–286.

[3] Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists’ Perspectiveon Coronavirus Disease 19 (COVID-19). Indian Journal of Pediatrics. 2020, 87: 281–286.

[4] Pergolizzi JV Jr, Raffa RB, Varrassi G, Magnusson P, LeQuang JA, Paladini A, et al. Potential neurological manifestations of COVID-19: a narrative review. Postgrad Med. 2021; 1–11.

[5] Johns Hopkins University. Mortality Analyses. 2021. Available at: https://coronavirus.jhu.edu/data/mortality (Accessed: 13 May 2021).

[6] National Center for Immunization and Respiratory Diseases. People at Increased Risk. 2021. Available at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/index. html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2...

(Accessed: 5 February 2021).

[7] Maragakis L. Coronavirus and COVID- 19: Who is at Higher Risk?2020. Available at: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-and-covid19-who-is-at-higher-risk (Accessed: 17 December 2020).

[8] Osei AD, Mirbolouk M, Orimoloye OA, Dzaye O, Uddin SMI, Benjamin EJ, et al. Association between E-Cigarette Use and Chronic Obstructive Pulmonary Disease by Smoking Status: Behavioral Risk Factor Surveillance System 2016 and 2017. American Journal of Preventive Medicine. 2020; 58: 336–342.

[9] Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products. 2020. Available at: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html (Accessed: 17 December 2020).

[10] McAlinden KD, Eapen MS, Lu W, Sharma P, Sohal SS. The rise of electronic nicotine delivery systems and the emergence of electronic-cigarette-driven disease. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2020; 319: L585–L595.

[11] US Department of Health and Human Services. E-Cigarette Use Among Youth and Young Adults. A Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention (US). 2016.

[12] Kashyap VK, Dhasmana A, Massey A, Kotnala S, Zafar N, Jaggi M, et al. Smoking and COVID- 19: Adding Fuel to the Flame. International Journal of Molecular Sciences. 2020; 21: 6581.

[13] Kaur G, Lungarella G, Rahman I. SARS-CoV-2 COVID-19 Susceptibility and Lung Inflammatory Storm by Smoking and aping. Journal of Inflammation Research. 2020; 17: 21.

[14] Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, et al. Analysis of Factors Associated with Disease Outcomes in Hospitalized Patients with 2019 Novel Coronavirus Disease. Chinese Medical Journal. 2020; 133: 1032–1038.

[15] Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). Journal of Clinical Medicine. 2020; 9: 841.

[16] McAlinden KD, Eapen MS, Lu W, Chia C, Haug G, Sohal SS. COVID-19 and vaping: risk for increased susceptibility to SARS-CoV-2 infection?European Respiratory Journal. 2020; 56: 2001645.

[17] Li D, Croft DP, Ossip DJ, Xie Z. The association between statewide vaping prevalence and COVID-19. Preventive Medicine Reports. 2020; 20: 101254.

[18] Sifat AE, Nozohouri S, Villalba H, Vaidya B, Abbruscato TJ. The Role of Smoking and Nicotine in the Transmission and Pathogenesis of COVID-19. Journal of Pharmacology and Experimental Therapeutics. 2020; 375: 498–509.

[19] Singh AG, Chaturvedi P. Tobacco Use and Vaping in the COVID-19 Era. Head Neck. 2020, 42:1240–1242.

[20] Singh J, Luquet E, Smith DPT, Potgieter HJ, Ragazzon P. Toxicological and Analytical Assessment of E-Cigarette Refill Components on Airway Epithelia. Science Progress. 2016; 99: 351–398.

[21] Callahan-Lyon P. Electronic cigarettes: human health effects. Tobacco Control. 2014; 23: ii36–ii40.

[22] Stoebner A, Le Faou A, Huteau M, Gricourt Y, Cuvillon P. E-cigarette or Vaping product use Associated Lung Injury (EVALI): Health issues going beyond anaesthetic and surgical perioperative procedures. Anaesthesia Critical Care & Pain Medicine. 2019; 38: 563–564.

[23] Blagev DP, Harris D, Dunn AC, Guidry DW, Grissom CK, Lanspa MJ. Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping: a prospective observational cohort study. Lancet. 2019; 394: 2073–2083.

[24] Archie SR, Cucullo L. Cerebrovascular and Neurological Dysfunction Under the Threat of COVID-19: Is There a Comorbid Role for Smoking and Vaping? International Journal of Molecular Sciences. 2020; 21: 3916.

[25] Laucks P, Salzman GA. The Dangers of Vaping. Missouri Medicine. 2020; 117: 159–164.

[26] Buchanan ND, Grimmer JA, Tanwar V, Schwieterman N, Mohler PJ, Wold LE. Cardiovascular Risk of Electronic Cigarettes: A Review of Preclinical and Clinical Studies. Cardiovascular Research. 2020; 116: 40–50.

[27] National Center for Immunization and Respiratory Diseases. People with Certain Medical Conditions. 2021. Available at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html (Accessed: 4 February 2021).

[28] National Center for Health Statistics. Weekly Updates by Select Demographic and Geographic Characteristics. 2021. Available at: https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index. htm (Accessed: 25 April 2021).

[29] National Center for Immunization and Respiratory Diseases. Risk for COVID-19 Infection, Hospitalization, and Death by Age Group. 2021. Available at: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html (Accessed: 25 April 2021).

[30] Centers for Disease Control and Prevention. Laboratory-Confirmed COVID-19-Associated Hospitalizations. 2021. Available at: https://gis.cdc.gov/grasp/covidnet/COVID19_5.html (Accessed: 25 April 2021).

[31] Kopa PN, Pawliczak R. IQOS–a heat-not-burn (HnB) tobacco product—chemical composition and possible impact on oxidative stress and inflammatory response. a systematic review. Toxicology Mechanisms and Methods. 2019; 30: 81–87.

[32] Herr C, Tsitouras K, Niederstraßer J, Backes C, Beisswenger C, Dong L, et al. Cigarette smoke and electronic cigarettes differentially activate bronchial epithelial cells. Respiratory Research. 2020; 21: 67.

[33] Arastoo S, Haptonstall KP, Choroomi Y, Moheimani R, Nguyen K, Tran E, et al. Acute and chronic sympathomimetic effects of e-cigarette and tobacco cigarette smoking: role of nicotine and non-nicotine constituents. American Journal of Physiology-Heart and Circulatory Physiology. 2020; 319: H262–H270.

[34] Vansickel AR, Cobb CO, Weaver MF, Eissenberg TE. A Clinical Labo-ratory Model for Evaluating the Acute Effects of Electronic “Cigarettes”: Nicotine Delivery Profile and Cardiovascular and Subjective Effects. Cancer Epidemiology Biomarkers & Prevention. 2010; 19: 1945–1953.

[35] Flouris AD, Poulianiti KP, Chorti MS, Jamurtas AZ, Kouretas D, Owolabi EO, et al. Acute effects of electronic and tobacco cigarette smoking on complete blood count. Food and Chemical Toxicology. 2012; 50: 3600–3603.

[36] Flouris AD, Chorti MS, Poulianiti KP, Jamurtas AZ, Kostikas K, Tzatzarakis MN, et al. Acute impact of active and passive electronic cigarette smoking on serum cotinine and lung function. Inhalation Toxicology. 2013; 25: 91–101.

[37] Chorti M, Poulianti K, Jamurtas A, Kostikas K. Effects of Active and Passive Electronic and Tobacco Cigarette Smoking on Lung Function. Toxicology Letters. 2012; 211: S64.

[38] Farsalinos K, Tsiapras D, Kyrzopoulos S, et al. Acute Effects of Using an Electronic Nicotine-Delivery Device (E-Cigarette) on Myocardial Function: Comparison with the Effects of Regular Cigarettes. European Heart Journal. 2014; 14: 78.

[39] Tzatzarakis MN, Tsitoglou KI, Chorti MS, Poulianiti KP, Jamurtas AZ, Koutedakis Y, et al. Acute and short term impact of active and passive tobacco and electronic cigarette smoking on inflammatory markers. Toxicology Letters. 2013; 221: S86.

[40] National Center for Health Statistics. Percentage of Adults Who Had Ever Used an E-Cigarette, by Sex, Age, Race and Hispanic Origin, and Poverty status: United States, 2018. 2018. Available at: https://www.cdc.gov/nchs/images/databriefs/351-400/db365-fig1.png (Accessed: 6 February 2021).

[41] Levine JA. Poverty and Obesity in the U.S. Diabetes. 2011; 60: 2667–2668.

[42] Knighton AJ, Brunisholz KD, Savitz ST. Detecting Risk of Low Health Literacy in Disadvantaged Populations Using Area-Based Measures. Generating Evidence & Methods to Improve Patient Outcomes. 2017; 5: 7.

[43] Salah HM, Sharma T, Mehta J. Smoking Doubles the Mortality Risk in COVID-19: a Meta-Analysis of Recent Reports and Potential Mechanisms. Cureus. 2020; 12: e10837.

[44] Kramarow E. Health of Former Cigarette Smokers Aged 65 and Over: United States, 2018. National Health Statistics Report. 2020; 145: 1–12.

[45] Griffith DM, Sharma G, Holliday CS, Enyia OK, Valliere M, Semlow AR, et al. Men and COVID-19: A Biopsychosocial Approach to Understanding Sex Differences in Mortality and Recommendations for Practice and Policy Interventions. Preventing Chronic Disease. 2020; 17: 200247.

[46] World Health Organization. 10 Facts on Gender and Tobacco. 2010. Available at: https://www.who.int/gender/documents/ 10facts_gender_tobacco_en.pdf (Accessed: 6 February 2021).

[47] González-Rubio J, Navarro-López C, López-Nájera E, López-Nájera A, Jiménez-Díaz L, Navarro-López JD, et al. A Systematic Review and Meta-Analysis of Hospitalised Current Smokers and COVID-19. International Journal of Environmental Research and Public Health. 2020; 17: 7394.

[48] Garufi G, Carbognin L, Orlandi A, Tortora G, Bria E. Smoking habit and hospitalization for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: the unsolved paradox behind the evidence. European Journal of Internal Medicine. 2020; 77: 121–122.

[49] Berlin I, Thomas D. Does Smoking Protect Against Being Hospitalized for COVID-19? International Journal of Environmental Research and Public Health. 2020; 17: 9559.

[50] Siegel MB, Tanwar KL, Wood KS. Electronic Cigarettes as a Smoking-Cessation: Tool Results from an Online Survey. American Journal of Preventive Medicine. 2011; 40: 472–475.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 0.5(2019) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time

Conferences

Top